A federal court recently struck down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs. Precision's Ryan Cox and Reta Mourad weigh in on why the decision may spur more pushback against these copay programs.
The COVID-19 pandemic served as a catalyst for the expansion and uptake of telehealth and virtual care for office visits and outpatient care, which rose from less than 1% utilization in 2019 to more than 50% at the height of the pandemic in 2020. Now, as the pandemic stabilizes, virtual care visits have declined significantly and have largely stabilized at about 10% of health care visits. Precision's Elizabeth Oyekan and Reta Mourad discuss three reasons that virtual care and telehealth care are here to stay.
Dive into the evolving PBM landscape as PRECISIONvalue's Sejal Jonas explores tactics to bring new DUM tools to the market to effectively manage drug costs and spend.
PRECISIONvalue's Ryan Cox examines the increasing level of influence IDNs have over drug therapy prescribing and what tools they are leveraging to manage drug costs and spend.
PRECISIONvalue's Barbara Henry points out that while DUMs are a vital cost-savings tool, the administrative burden can be extremely high. In this overview, she offers some new strategies to minimize the administrative impact while still controlling cost.
PRECISIONvalue's Dorothy Agyemang and Elizabeth Oyekan do a deep dive into some of CMS’s current and proposed actions, focusing on both offense and defense tactics to address the rising costs of drugs.
We are happy to announce that PRECISIONvalue has made the list of MM&M’s Top 100 North American healthcare agencies of 2022!
Our employer expert Jorge Font addresses concerns about the increasing numbers of “seven-figure costs” associated with emerging gene therapy and some of the considerations undertaken to address these rising costs.
A federal court recently struck down a CMS final rule slated to take effect in 2023 which would have required pharmaceutical manufacturers to ensure that financial assistance provided to patients goes only to patients and not to payers under their copay accumulator and maximizer programs. Despite the ruling, Precision's Ryan Cox and Reta Mourad discuss how the renewed attention to these programs could spur more states to take action of their own against them.
Diabetes deaths in the United States continue to surge well above pre-pandemic levels with over 100,000 Americans dying from diabetes in 2021. Increasing deaths from diabetes is a clear call to action for new solutions. Historically, diabetes has been treated as a chronic disease, managed with a lifetime of medications. However, a new line of thinking about diabetes remission permeates the literature.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
